1. A method of treating multiple sclerosis in a subject, comprising administering to said subject an immunomodulator； and administering to the subject twice daily a sustained release composition containing 10 mg of 4-aminopyridine. ! 2. The method according to claim 1, wherein said immunomodulator is selected from interferons, natalizumab, glatiramer acetate, and combinations thereof. ! 3. A method for treating spasticity in a subject associated with multiple sclerosis, comprising administering to said subject twice daily a sustained release composition containing 10 mg of 4-aminopyridine, in which the spasticity of said subject is reduced. ! 4. A method for treating multiple sclerosis in a subject, comprising:! measuring creatinine clearance in said patient； and! administering to the subject twice a day a sustained release composition containing 10 mg of 4-aminopyridine if the creatinine clearance of said subject is greater than or equal to 30 ml / min. ! 5. The method according to claim 4, in which the measurement of creatinine clearance in said patient takes place before the initial administration of said sustained release composition containing 10 mg of 4-aminopyridine. ! 6. The method according to claim 4, in which the measurement of creatinine clearance of said patient occurs during the treatment period. ! 7. The method of claim 4, wherein administering to the subject twice a day a sustained release composition containing 10 mg of 4-aminopyridine continues until the creatinine clearance of said subject is less than 30 ml / min. ! 8. A method of treating multiple sclerosis in a subject, comprising:! measurement in said patient1. Способ лечения рассеянного склероза у субъекта, включающий введение упомянутому субъекту иммуномодулятора； и введение упомянутому субъекту два раза в день композиции с замедленным высвобождением, содержащей 10 мг 4-аминопиридина. ! 2. Способ по п.1, в котором упомянутый иммуномодулятор выбран из интерферонов, натализумаба, глатирамера
